Cargando…
Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis
Currently, there is an urgent need to find a treatment for the highly infectious coronavirus disease (COVID-19). However, the development of a new, effective, and safe vaccine or drug often requires years and poses great risks. At this critical stage, there is an advantage in using existing clinical...
Autores principales: | Hou, Yajing, Ge, Shuai, Li, Xiaowei, Wang, Cheng, He, Huaizhen, He, Langchong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889471/ https://www.ncbi.nlm.nih.gov/pubmed/33609497 http://dx.doi.org/10.1016/j.cbi.2021.109420 |
Ejemplares similares
-
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus
por: Wang, Nan, et al.
Publicado: (2020) -
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
por: Ge, Shuai, et al.
Publicado: (2021) -
Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2
por: Ge, Shuai, et al.
Publicado: (2021) -
Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2
por: Zhang, Yongjing, et al.
Publicado: (2021) -
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine
por: Glass, Daniel J, et al.
Publicado: (2003)